HIV entry blocker pairs CD4 mimic and antibody, showing sevenfold higher efficacy

Drug conjugates (ADCs) developed at Institute of Science Tokyo combine a CD4 mimic with neutralizing antibodies for enhanced suppression of human immunodeficiency virus (HIV) infection. By targeting the gp120 on the viral envelope via a two-step…

Continue Reading

News Source: medicalxpress.com